Form 4: Nexalin Director Granted 100,000 Stock Options

Nexalin Technology Director Alan Kazden was granted 100,000 stock options at an exercise price of $0.83, contingent on future shareholder approval.

Summary

• Alan Kazden, a Director of Nexalin Technology, Inc. (NXL), was granted 100,000 stock options.
• The options have an exercise price of $0.83 per share.
• The grant date and exercisable date is December 19, 2025, with an expiration date of December 19, 2030.
• The grant is made under the 2023 Equity Incentive Plan.
• The grant is subject to shareholder approval to increase the plan limit under NASDAQ rules.
• Following this transaction, Alan Kazden beneficially owns a total of 362,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of future-dated options is a standard incentive mechanism, but the contingency of shareholder approval and the unusual future transaction date introduce elements of uncertainty rather than clear positive or negative financial performance.

Positives

• Granting of stock options to a director aligns management incentives with shareholder interests for future stock price appreciation.
• The exercise price of $0.83 provides a clear target for stock appreciation that the company aims to achieve.

Negatives

• The reported transaction date (December 19, 2025) is in the future, which is highly unusual for a Form 4 filing that typically reports past events.
• The stock option grant is contingent on shareholder approval to increase the 2023 Equity Incentive Plan limit under NASDAQ rules, introducing uncertainty regarding its finalization.

Risks

• The primary risk is that the shareholder approval required to increase the 2023 Equity Incentive Plan limit under NASDAQ rules may not be obtained, potentially invalidating or altering the terms of the option grant.
• The future-dated transaction (December 19, 2025) introduces ambiguity regarding the immediate impact and the precise nature of the grant, as Form 4s typically report completed transactions.
• The value of the options is dependent on Nexalin Technology's stock price exceeding the $0.83 exercise price by the expiration date of December 19, 2030.

Future Outlook

The grant of future-dated stock options suggests an intention to incentivize the director for future performance, contingent on shareholder approval of an increased equity plan limit.

Management Comments

• Granted under the 2023 Equity Incentive Plan, subject to Shareholder Approval to increase the Plan limit under NASDAQ Rules.

Industry Context

Granting stock options is a common practice in the technology and medical device sectors to attract, retain, and incentivize key personnel, aligning their interests with long-term company performance and growth.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across many industries, particularly in growth-oriented companies.
• The requirement for shareholder approval for increasing the plan limit is a standard corporate governance measure to ensure alignment with shareholder interests, as seen in companies like Tesla (TSLA) or Apple (AAPL) when they seek to expand their equity compensation pools.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential alignment of director's interests with stock price appreciation. Will need to vote on the plan limit increase.
• Management/Directors: Alan Kazden receives additional incentive compensation, contingent on shareholder approval.

Next Steps

• Shareholders will need to vote on increasing the 2023 Equity Incentive Plan limit under NASDAQ rules.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director, which is a standard compensation practice. While it aligns the director's interests with future stock performance, it does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. The future date of the transaction and the contingency of shareholder approval are noted but do not fundamentally alter the investment thesis based solely on this filing.

Keywords

Nexalin Technology, NXL, Stock Options, Equity Incentive Plan, Director Compensation, Insider Transaction, Form 4, Shareholder Approval